This inventor holds 2 USPTO granted patents. Top assignee: The United States of America, as Represented by the Secretary, Department of Health and Human Services. Active years: 2021-2026.
Company Filing History:
Years Active: 2021-2026
Title: Sanjivan Gautam: Innovator in T Cell Therapy
Introduction
Sanjivan Gautam is a prominent inventor based in Rockville, MD (US). He has made significant contributions to the field of immunotherapy, particularly in the development of T cell therapies aimed at enhancing anti-tumor activity. With a total of 2 patents, his work is paving the way for innovative treatments in cancer care.
Latest Patents
One of Sanjivan Gautam's latest patents is titled "T CELLS HAVING ENHANCED ANTI-TUMOR ACTIVITY." This patent describes T cells that have been modified to overexpress c-Myb, a transcription factor that plays a crucial role in T cell function. The patent provides details on an isolated or purified T cell that comprises an antigen-specific receptor, such as a T cell receptor (TCR) or a chimeric antigen receptor (CAR). The modified T cell expresses the transcription factor at a higher level than unmodified T cells, which enhances its anti-tumor capabilities. Additionally, the patent outlines related populations of cells, pharmaceutical compositions, methods of treating diseases, and methods for inhibiting the differentiation of T cells.
Career Highlights
Sanjivan Gautam works for the United States of America, as represented by the Secretary, Department of Health and Human Services. His role involves significant research and development in the field of health services, particularly focusing on innovative therapies that can improve patient outcomes.
Collaborations
Sanjivan has collaborated with notable colleagues in his field, including Luca Gattinoni and Warren Jaye Leonard. These collaborations have further enriched his research and contributed to the advancement of T cell therapies.
Conclusion
Sanjivan Gautam is a key figure in the development of advanced T cell therapies, with a focus on enhancing their anti-tumor activity. His innovative patents and collaborations highlight his commitment to improving cancer treatment options. His work continues to inspire advancements in immunotherapy and patient care.